Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants...
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock BOULDER, Colo., April 2, 2025 /PRNewswire/ — Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing...
TigerConnect to Launch Pre-Hospital and Transfer Solutions to Streamline Emergency Care Coordination and Improve Patient Throughput at HIMSS 25 New solutions combined with feature enhancements to the current portfolio, including the addition of an AI assistant for...
Cleerly Unveils Groundbreaking Late-Breaking Clinical Trial Results Demonstrating AI-QCT’s Predictive Power for Women’s Cardiovascular Risk at ACC.25 New Findings from the CONFIRM2 Registry Reveal Significant Gender Disparities in Coronary Plaque Features and...
Recent Comments